Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Gastrointestinal Cancers
•
Esophageal Cancer
•
Liver and Pancreas Tumors
•
Internal Medicine
•
Gastroenterology
•
Advanced Endoscopy
How do you manage upper esophageal squamous cell in situ disease that is not amenable to endoscopic mucosal resection?
Related Questions
How would you manage a solitary unresectable liver metastasis?
Would you consider chemo-RT for duodenal adenocarcinoma s/p resection with at least 1 cm positive margin in a patient with a history of Crohn's disease?
How would active Crohn's on Adalimumab affect the adjuvant management of a T2aN0M0 gallbladder cancer?
In patients with perihilar cholangiocarcinoma eligible for liver transplant, what is the protocol for neoadjuvant chemo-RT, particularly when brachytherapy is not available?
What dose constraints and how much CTV do you extend into stomach for a patient with a GEJ tumor being treated with pre-operative or definitive chemo-RT?
How would you manage a middle thoracic esophageal squamous cell carcinoma (tumor is 25-30 cm from carina) with a positive supra-clavicular lymph node?
Would you offer chemoRT to a colon cancer case with a resected polyp with positive margins if the patient wishes to avoid surgery?
How long should surgery be delayed in a patient with localized, resectable pancreatic cancer who developed acute pancreatitis following EUS guided biopsy?
Is there a role for radiation in palliating malignant small bowel obstruction?
What do you consider an optimal interval of time to repeat necrosectomies for treatment of WON?
